 The primary purpose of this study is to determine the maximum tolerated dose and dose-limiting toxicities DLTs of weekly and every 3-weeks ABI-007 in combination with carboplatin area under the curve AUC6 in patients with ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. 